Xeris Biopharma Holdings Inc XERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
-
Xeris Announces Details for XP-8121 Program Overview Webinar
-
Xeris Biopharma Reports Second Quarter 2026 Financial Results
-
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Trading Information
- Previous Close Price
- $10.48
- Day Range
- $10.33–10.55
- 52-Week Range
- $5.25–11.33
- Bid/Ask
- $10.46 / $10.99
- Shares Outstanding
- 182.32M
- Market Cap
- $1.91B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 174.33
- Price/Sales
- 5.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.11%
Company Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 435
- Website
- https://www.xerispharma.com
Valuation
|
Metric
|
XERS
|
|---|---|
Price/Earnings (Normalized) | 174.33 |
Price/Book Value | — |
Price/Sales | 5.63 |
Price/Cash Flow | 32.54 |
Price/Earnings
XERS
Financial Strength
|
Metric
|
XERS
|
|---|---|
Quick Ratio | 0.95 |
Current Ratio | 1.45 |
Interest Coverage | 0.21 |
Quick Ratio
XERS
Profitability
|
Metric
|
XERS
|
|---|---|
Return on Assets (Normalized) | 11.03% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 24.55% |
Return on Assets
XERS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|B#Y?<>>d | LOCK|@f$yW | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|phb?s<WB | LOCK|&&^#V | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|D@dSzbL | LOCK|## | $41B | |||
| Zoetis Inc Class A
ZTS
| LOCK|>bML>V$s | LOCK|ZX | $31B | |||
| Viatris Inc
VTRS
| LOCK|qC?S@> | LOCK|P%! | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|y>$ | LOCK|&&M | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|!@FvXR | LOCK|Z&$ | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|MH%F!T | LOCK|@# | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|H>fnn? | LOCK|XJ%z | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|R@p?q@ | LOCK|<! | $2B |
United States